TT-173

Unassigned

New Medicines

Haemorrhage following total knee arthroplasty

Information

New molecular entity
Thrombotargets
Thrombotargets

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

Yeast-derived microvesicles containing glycosylated recombinant human tissue factor, formulated as a room temperature-stable lyophilisate for suspension and a powder for reconstitution
TKA involves extensive soft tissue release & bone incisions, resulting in significant blood loss. Allogenic blood transfusions are generally used to prevent postoperative anaemia but are associated with additional risks, e.g. transmission of infectious disease, transfusion-related acute lung injury, haemolytic reactions, fluid overload, increased rate of postop infection, and immunosuppression [1]. Total number of TKAs in England, Wales & Northern Ireland was 106,334 in 2017 [2].
Haemorrhage following total knee arthroplasty
Topical